Related Experiment Video
Updated: Jan 30, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket
Mohan R Pradhan1,2, Jia Wei Siau3, Srinivasaraghavan Kannan1
1Bioinformatics Institute, A*STAR (Agency for Science, Technology and Research), 30 Biopolis Street, #07-01 Matrix, Singapore 138671.
Abstract:
The DNA binding domain (DBD) of the tumor suppressor p53 is the site of several oncogenic mutations. A subset of these mutations lowers the unfolding temperature of the DBD. Unfolding leads to the exposure of a hydrophobic β-strand and nucleates aggregation which results in pathologies through loss of function and dominant negative/gain of function effects. Inspired by the hypothesis that structural changes that are associated with events initiating unfolding in DBD are likely to present opportunities for inhibition, we investigate the dynamics of the wild type (WT) and some aggregating mutants through extensive all atom explicit solvent MD simulations. Simulations reveal differential conformational sampling between the WT and the mutants of a turn region (S6-S7) that is contiguous to a known aggregation-prone region (APR). The conformational properties of the S6-S7 turn appear to be modulated by a network of interacting residues. We speculate that changes that take place in this network as a result of the mutational stress result in the events that destabilize the DBD and initiate unfolding. These perturbations also result in the emergence of a novel pocket that appears to have druggable characteristics. FDA approved drugs are computationally screened against this pocket.
Insights
Mutations in the p53 DNA binding domain (DBD) can cause unfolding and aggregation. Researchers used simulations to find a new druggable pocket in the p53 DBD, offering potential therapeutic targets.
Area of Science:
- Biochemistry
- Structural Biology
- Computational Biology
Background:
- The p53 tumor suppressor's DNA binding domain (DBD) is frequently mutated in cancer.
- Certain mutations destabilize the DBD, leading to unfolding, aggregation, and associated pathologies.
Purpose of the Study:
- To investigate the dynamics of wild-type (WT) and mutant p53 DBDs using molecular dynamics (MD) simulations.
- To identify structural changes that initiate DBD unfolding and explore potential therapeutic inhibition strategies.
Main Methods:
- Extensive all-atom explicit solvent molecular dynamics (MD) simulations.
- Computational screening of FDA-approved drugs against identified pockets.
Main Results:
- MD simulations revealed differential conformational sampling in the S6-S7 turn region between WT and mutant p53 DBDs.
- A novel, druggable pocket was identified in the destabilized mutant DBDs.
- Computational screening identified potential drug candidates for this pocket.
Conclusions:
- Mutations in the p53 DBD can trigger unfolding via destabilization of a contiguous turn region.
- The identified druggable pocket presents a promising target for developing inhibitors against oncogenic p53 mutants.
Related Concept Videos
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
Single-Strand DNA Binding Proteins
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
The Equilibrium Binding Constant and Binding Strength
Ligand Binding and Linkage
Cooperative Binding of Transcription Regulators

